CIC
HZNP

Carnegie Investment Counsel’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Carnegie Investment Counsel’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,775
Closed -$321K – 505
2023
Q3 		$321K Sell
2,775
-443
-14% -$47.6K 0.01% 401
2023
Q2 		$331K Sell
3,218
-8
-0.2% -$844 0.01% 410
2023
Q1 		$352K Buy
3,226
+1,088
+51% +$120K 0.01% 406
2022
Q4 		$243K Buy
+2,138
New +$178K 0.01% 453

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Carnegie Investment Counsel's HZNP Position: Q4 2023 in Review

Carnegie Investment Counsel sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,775 shares — an estimated $321K sold.

Carnegie Investment Counsel first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $352K in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Carnegie Investment Counsel reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Carnegie Investment Counsel sold 2,775 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $321K.
  • Carnegie Investment Counsel first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Carnegie Investment Counsel's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $352K in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Carnegie Investment Counsel's 13F filing for Q4 2023, filed 30 Jan 2024.